First Results of Avicidin Trials

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 4
Volume 4
Issue 4

SEATTLE--NeoRx Corporation reports that in phase I/II dose escalation studies, Avicidin produced a 10-fold improvement in tumor-to-blood ratios over conventional radioimmunotherapy, approaching the ratios achieved in animal studies.

SEATTLE--NeoRx Corporation reports that in phase I/II dose escalationstudies, Avicidin produced a 10-fold improvement in tumor-to-bloodratios over conventional radioimmunotherapy, approaching the ratiosachieved in animal studies.

Avicidin, a monoclonal antibody/yttrium-90 product, employs NeoRx'sproprietary pretargeting technology in which the radionuclideand antibody are injected separately rather than linked together.The radionuclide either attaches to the antibody that is pretargetedto the tumor or quickly exits the body, reducing radiation exposureto normal tissues, NeoRx said.

Recent Videos
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Greater cancer treatment longevity enables oncologists the ability to form more impactful relationships with their patients.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content